ProCE Banner Activity

Our Experiences and Considerations With Current and Emerging BTK Inhibitors for R/R CLL/SLL

Clinical Thought

Expert faculty address audience questions from a live event and discuss their experience and considerations with current and emerging BTK inhibitors in R/R CLL/SLL. 

Released: December 26, 2023

Share

Faculty

Jennifer R. Brown

Jennifer R. Brown, MD, PhD

Director, CLL Center & Institute Physician
Dana-Farber Cancer Institute
Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
Boston, Massachusetts 

Florence Cymbalista

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Merck Sharp & Dohme, LLC.

Lilly

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

Jennifer R. Brown, MD, PhD

Director, CLL Center & Institute Physician
Dana-Farber Cancer Institute
Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
Boston, Massachusetts 

Jennifer R. Brown, MD, PhD: consultant/advisor/speaker: AbbVie, Acerta/AstraZeneca, Alloplex, Beigene, Biotherapeutics, Genentech/Roche, Grifols Worldwide Operations, IOnctura, Kite, Loxo/Lilly, Merck, Numab Therapeutics, Pfizer, Pharmacyclics; researcher: BeiGene, Gilead, IOnctura, Loxo/Lilly, MEI Pharma, SecuraBio, TG Therapeutics.

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Florence Cymbalista, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Beigene, Janssen, Lilly.